Fig. 2From: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapya 5-year disease-specific survival (DSS). b 5-year disease-free survival (DFS). c High tumor PD-L1 (+) (> 20%) expression (positive = 1, negative = 0) and disease-specific survival. d High tumor PD-L1 (+) (> 20%) expression (positive = 1, negative = 0) and disease-free survivalBack to article page